COLL vs CVS

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 21. 1x trailing P/E (5. 0x forward), making it the more compelling value choice. Analysts rate Collegium Pharmaceutical, Inc. (COLL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 21. 1x versus CVS Health Corporation at 62. 5x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 5. 0x.

Over the past 5 years, Collegium Pharmaceutical, Inc.

(COLL) delivered a total return of +66. 4%, compared to +18. 4% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: COLL returned +141. 8% versus CVS's +3. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Collegium Pharmaceutical, Inc. 's 0. 65β — meaning COLL is approximately 1181% more volatile than CVS relative to the S&P 500. On balance sheet safety, CVS Health Corporation (CVS) carries a lower debt/equity ratio of 124% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Collegium Pharmaceutical, Inc. grew EPS -7. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COLL leads at 24. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — COLL leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 5. 0x forward P/E versus 12. 1x for CVS Health Corporation — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COLL: 58. 9% to $58. 00.

In this comparison, CVS (3.

1% yield) pays a dividend. COLL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 9%, COLL: +141. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COLL is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while COLL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.